Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655823 · ClinicalTrials.gov registry record · Phase 2
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
A Phase 2 study, sponsored by Wex Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT01655823: Clinical Trial Phase 2 study, sponsored by Wex Pharmaceuticals.
NCT01655823 is a Phase 2 study that was terminated before completion, run by Wex Pharmaceuticals. The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01655823, a Phase 2 study, was terminated before completion, sponsored by Wex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in greater than 40% of patients. To improve the peripheral neuropathy, the chemotherapy dosing is often either decreased or discontinued potentially affecting tumor responsiveness, prognosis, and survival. There is an unmet medical need for treatment of cancer patients with chemotherapy induced neuropathic pain (CINP) and the proposed study will investigate the efficacy and safety of multiple dose levels of tetrodotoxin (TTX) versus placebo in moderate to severe neuropathic pain caused by chemotherapy.
Interventions
- DRUG Placebo
- DRUG Tetrodotoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01655823
The ClinicalTrials.gov registry entry for NCT01655823 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wex Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01655823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01655823 about?
NCT01655823 is a clinical study titled "The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment". Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone. Chemotherapy-induced peripheral neuropathy commonly occurs in greater than 40% of patients. To...
What is the current status of trial NCT01655823?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2012-07. Estimated completion is 2015-02-11.
What interventions are being tested in trial NCT01655823?
The interventions under investigation include: Placebo (DRUG), Tetrodotoxin (DRUG).
Who is sponsoring clinical trial NCT01655823?
This trial is sponsored by Wex Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.